Invasive tubular breast carcinoma
diseaseOn this page
Also known as breast tubular adenocarcinomainfiltrating tubular breast carcinomainfiltrating tubular carcinoma of breastinfiltrating tubular carcinoma of the breastinvasive tubular carcinoma of breastinvasive tubular carcinoma of the breasttubular breast cancertubular breast carcinomatubular carcinoma of breasttubular carcinoma of the breast
Summary
Invasive tubular breast carcinoma (MONDO:0003936) is a cancer and 10 clinical trials. Top therapeutic interventions include carboplatin, epirubicin, and ferric carboxymaltose. A subtype of invasive ductal breast carcinoma — broader associated-gene and molecular evidence is on the parent page (see Disease family below).
At a glance
- Classification: Cancer
- Clinical trials: 10
Clinical features
No curated clinical features (Orphanet) for this disease.
Identifiers
Disease identifiers
| Field | Value |
|---|---|
| Canonical name | invasive tubular breast carcinoma |
| Mondo ID | MONDO:0003936 |
| DOID | DOID:6587 |
| NCIT | C9135 |
| UMLS | C1328544 |
| MedGen | 230969 |
| Anatomy (UBERON) | UBERON:0000310 |
| Is cancer (heuristic) | yes |
Also known as: breast tubular adenocarcinoma · infiltrating tubular breast carcinoma · infiltrating tubular carcinoma of breast · infiltrating tubular carcinoma of the breast · invasive tubular breast carcinoma · invasive tubular carcinoma of breast · invasive tubular carcinoma of the breast · tubular breast cancer · tubular breast carcinoma · tubular carcinoma of breast · tubular carcinoma of the breast
Disease family
This is a subtype of invasive ductal breast carcinoma. Genetic, therapeutic, and trial evidence is largely curated at the broader-term level — see the parent page for the associated-gene cohort and molecular evidence.
Classification path: disease › human disease › disease by body system or component › integumentary system disorder › integumentary system cancer › breast adenocarcinoma › breast ductal adenocarcinoma › invasive ductal breast carcinoma › invasive tubular breast carcinoma
Related subtypes (9): breast mucinous carcinoma, breast secretory carcinoma, glycogen-rich clear cell breast carcinoma, acinic cell breast carcinoma, scirrhous breast carcinoma, basal-like breast carcinoma, invasive ductal and lobular carcinoma, medullary breast carcinoma, pleomorphic breast carcinoma
Genetics & variants
GWAS landscape
No GWAS associations recorded — common-variant (GWAS) studies don’t cover this disease (typical for Mendelian / rare diseases). See the curated gene cohort and Mendelian overlap below.
Variant details and genetic-evidence tiers
No tiered GWAS variants or ClinVar records for this disease.
Genes & proteins
No associated-gene cohort resolved for this disease. Atlas builds the molecular and therapeutic sections — associated genes, protein families, druggability, pathways, interactions, and drug associations — by aggregating over a disease’s associated genes (resolved via GWAS / GenCC / ClinVar / CIViC), and none resolved here. This is expected for antibody-mediated, autoimmune, or otherwise non-gene-defined conditions; the curated evidence for this disease is its clinical features, GWAS susceptibility, and clinical trials (above).
Function
No pathway enrichment — requires an associated-gene cohort.
Therapeutics
No druggable-target or therapeutic data for this disease’s cohort.
Clinical trials & evidence
Clinical trials
Clinical trials: 10.
Phase distribution (across all retrieved trials)
| Phase | Trials |
|---|---|
| PHASE3 | 5 |
| PHASE2 | 3 |
| PHASE2/PHASE3 | 2 |
Top trials by phase / activity
| NCT | Phase | Status | Title |
|---|---|---|---|
| NCT02221999 | PHASE2/PHASE3 | ACTIVE_NOT_RECRUITING | Weekly Paclitaxel and Cisplatin to Treat Hormone Receptor Positive and Triple Negative Breast Cancer Patients |
| NCT03201861 | PHASE3 | RECRUITING | Addition of Cisplatin to Adjuvant Chemotherapy for Early Stage Breast Cancer in High-Risk Women |
| NCT03414970 | PHASE3 | ACTIVE_NOT_RECRUITING | Hypofractionated Radiation Therapy After Mastectomy in Preventing Recurrence in Patients With Stage IIa-IIIa Breast Cancer |
| NCT01426880 | PHASE2/PHASE3 | COMPLETED | Addition of Carboplatin to Neoadjuvant Therapy for Triple-negative and HER2-positive Early Breast Cancer |
| NCT01583426 | PHASE3 | COMPLETED | Nanoparticle-based Paclitaxel vs Solvent-based Paclitaxel as Part of Neoadjuvant Chemotherapy for Early Breast Cancer (GeparSepto) |
| NCT02125344 | PHASE3 | COMPLETED | A Phase III Trial Comparing Two Dose-dense, Dose-intensified Approaches (ETC and PM(Cb)) for Neoadjuvant Treatment of Patients With High-risk Early Breast Cancer (GeparOcto) |
| NCT02879513 | PHASE3 | UNKNOWN | Trial of Adjuvant Chemotherapy in Breast Cancer Patients With Pathological Partial Response and Complete Response to Neoadjuvant Chemotherapy |
| NCT01754519 | PHASE2 | TERMINATED | Radiation Therapy in Treating Post-Menopausal Women With Early Stage Breast Cancer Undergoing Surgery |
| NCT02199418 | PHASE2 | COMPLETED | Addition of Cisplatin to Neoadjuvant Therapy for T Locally Advanced Breast Cancer |
| NCT02682693 | PHASE2 | COMPLETED | Denosumab as an add-on Neoadjuvant Treatment (GeparX) |
Drugs tested across these trials (top 30)
| Molecule | Max phase | Trials referencing |
|---|---|---|
| CARBOPLATIN | 4 | 3 |
| EPIRUBICIN | 4 | 2 |
| FERRIC CARBOXYMALTOSE | 4 | 1 |
| LETROZOLE | 4 | 1 |
| PERTUZUMAB | 4 | 1 |
| TRASTUZUMAB | 4 | 1 |
| ZENIDOLOL | 2 | 1 |